Anika EVP’s RSUs Vest; Shares Withheld for Tax

Anika Therapeutics EVP and General Counsel David Colleran reported routine equity compensation activity tied to previously granted restricted stock units (RSUs).

Rhea-AI Filing Summary

Anika Therapeutics EVP and General Counsel David Colleran reported routine equity compensation activity tied to previously granted restricted stock units (RSUs). On March 9, 2026, 5,465 RSUs from a March 9, 2023 grant vested and were converted into an equal number of common shares at no exercise price.

To cover tax withholding on the vesting, 1,919 common shares were retained by the company at a price of $14.96 per share, as a tax-withholding disposition rather than a market sale. After these transactions, Colleran directly holds 53,100 shares of Anika Therapeutics common stock.

Insider Trade Summary

5,465 shares exercised/converted

Exercise 3 txns

Insider Colleran David

Role EVP, General Counsel, Corp Sec

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	5,465	$0.00	$0.00
Exercise	Common Stock	5,465	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,919	$14.96	$29K

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 53,100 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
2. F2. Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025.
3. F3. Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.
4. F4. On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Anika Therapeutics (ANIK) report for David Colleran?

Anika Therapeutics reported that EVP and General Counsel David Colleran had 5,465 restricted stock units vest and convert into common shares. A portion of those shares was withheld to satisfy tax obligations related to the vesting event.

How many Anika Therapeutics RSUs vested for David Colleran in March 2026?

On March 9, 2026, 5,465 restricted stock units vested for David Colleran. Each unit represented the right to receive one share of Anika Therapeutics common stock, reflecting the final installment of a March 9, 2023 RSU grant.

Were any Anika Therapeutics (ANIK) shares sold by David Colleran in this Form 4?

The Form 4 shows no open-market sales by David Colleran. Instead, 1,919 common shares were withheld by the company at $14.96 per share solely to satisfy tax withholding obligations on vested restricted stock units.

What is David Colleran’s Anika Therapeutics share ownership after this Form 4?

Following the RSU vesting and related tax withholding, David Colleran directly holds 53,100 shares of Anika Therapeutics common stock. This total reflects his updated position after the March 9, 2026 equity compensation transactions.

What RSU grant does the March 2026 vesting for Anika’s David Colleran relate to?

The March 9, 2026 vesting relates to a grant of 16,395 restricted stock units awarded on March 9, 2023. Those RSUs vest in three equal annual installments, and the 2026 vesting represents the third and final installment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Colleran David

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel, Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		M		5,465	A	(1)	55,019(2)	D
Common Stock	03/09/2026		F		1,919(3)	D	$14.96	53,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/09/2026		M			5,465	(4)	(4)	Common Stock	5,465	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025.

3. Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.

4. On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

	/s/ David Colleran	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.